Ensign Peak Advisors, Inc Seagen Inc. Transaction History

Ensign Peak Advisors, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $883,177 - $1.18 Million	-6,529 Reduced 68.16%	3,050 $417,000
Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $247,433 - $407,796	-2,274 Reduced 19.19%	9,579 $1.7 Million
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $657,855 - $868,175	-5,500 Reduced 31.69%	11,853 $1.71 Million
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $1.41 Million - $1.89 Million	9,885 Added 132.36%	17,353 $2.68 Million
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $1.08 Million - $1.28 Million	-7,553 Reduced 50.28%	7,468 $1.27 Million

Q2 2021 Aug 13, 2021	SELL	$135.08 - $161.1 $426,177 - $508,270	-3,155 Reduced 17.36%	15,021 $2.37 Million
Q1 2021 May 12, 2021	SELL	$137.51 - $190.8 $2.44 Million - $3.39 Million	-17,761 Reduced 49.42%	18,176 $2.52 Million
Q4 2020 Feb 12, 2021	SELL	$164.63 - $211.93 $1.06 Million - $1.37 Million	-6,466 Reduced 15.25%	35,937 $6.29 Million
Q3 2020 Nov 12, 2020	BUY	$145.95 - $195.69 $6.19 Million - $8.3 Million	42,403 New	42,403 $8.3 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.